2022
Rilonacept for the treatment of recurrent pericarditis
Fava A, Reyaldeen R, Presti S, Goyal A, Akintoye E, Hughes D, Klein A. Rilonacept for the treatment of recurrent pericarditis. Expert Opinion On Biological Therapy 2022, 22: 7-16. PMID: 34757872, DOI: 10.1080/14712598.2022.2005024.Peer-Reviewed Original ResearchConceptsRecurrent pericarditisC-reactive proteinClinical trialsUpper respiratory tract infectionSafety of rilonaceptCommon adverse eventsRespiratory tract infectionsAvailable clinical trialsInjection site reactionsRapid clinical responseValuable therapeutic optionGood safety profilePromising new therapyIL-1β signalingDimeric fusion proteinGlucocorticoid-dependent diseasesAdverse eventsClinical responseTherapy durationTract infectionsSuccessful weaningRecurrence rateSafety profileTherapeutic optionsFuture trials
2017
Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification
Akintoye E, Briasoulis A, Afonso L. Biochemical risk markers and 10-year incidence of atherosclerotic cardiovascular disease: independent predictors, improvement in pooled cohort equation, and risk reclassification. American Heart Journal 2017, 193: 95-103. PMID: 29129262, DOI: 10.1016/j.ahj.2017.08.002.Peer-Reviewed Original ResearchConceptsPooled Cohort EquationsNet reclassification indexBiochemical risk markersBiomarker scoreCohort EquationsC-statisticRisk markersTreatment decisionsPrimary atherosclerotic cardiovascular disease (ASCVD) preventionAtherosclerotic cardiovascular disease preventionCategorical net reclassification indexSensitivity C-reactive proteinCategory-free net reclassification indexN-terminal prohormoneBrain natriuretic peptideAtherosclerotic cardiovascular diseaseCardiovascular disease preventionC-reactive proteinMulti-Ethnic StudyRate of incidentsASCVD preventionIndependent predictorsNet reclassificationNatriuretic peptideRisk reclassification